Tudor Investment Corp ET AL Has $18.75 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Tudor Investment Corp ET AL raised its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 44.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 735,027 shares of the biopharmaceutical company's stock after purchasing an additional 226,274 shares during the period. Tudor Investment Corp ET AL owned 0.12% of Royalty Pharma worth $18,751,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brooklyn Investment Group raised its holdings in shares of Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 876 shares during the last quarter. Allworth Financial LP lifted its position in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 877 shares in the last quarter. Riverview Trust Co grew its position in Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 1,186 shares in the last quarter. Fifth Third Bancorp increased its stake in Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 997 shares during the last quarter. Finally, Rakuten Securities Inc. increased its position in shares of Royalty Pharma by 160.5% during the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 1,003 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Stock Up 0.5 %

Royalty Pharma stock opened at $32.20 on Monday. The firm has a market capitalization of $18.56 billion, a price-to-earnings ratio of 22.21, a P/E/G ratio of 2.31 and a beta of 0.50. The firm has a 50 day simple moving average of $32.52 and a 200 day simple moving average of $29.45. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.73%. The ex-dividend date of this dividend is Friday, May 16th. Royalty Pharma's payout ratio is 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.